NTLA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $400,085.72

Intellia Therapeutics Insider Trading History Chart

Intellia Therapeutics Share Price & Price History

^$8.07

▼ -0.33 (-3.93%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

Intellia Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/29/2025	Muna Bhanji	Director	Sell	265	$9.97	$2,642.05	19,468
1/3/2025	John M Leonard	CEO	Sell	26,807	$12.18	$326,509.26	941,115
1/3/2025	Michael P Dube	CAO	Sell	1,372	$12.18	$16,710.96	45,640
1/2/2025	Eliana Clark	EVP	Sell	556	$12.03	$6,688.68	71,470
10/2/2024	Michael P Dube	CAO	Sell	2,012	$19.01	$38,248.12	47,012
7/1/2024	Eliana Clark	EVP	Sell	405	$22.93	$9,286.65	71,470
3/4/2024	James Basta	EVP	Sell	2,297	$32.99	$75,778.03	81,571
1/8/2024	Laura Sepp-Lorenzino	EVP	Sell	2,275	$28.87	$65,679.25	43,927
1/3/2024	David Lebwohl	EVP	Sell	5,843	$29.46	$172,134.78	54,372
1/3/2024	Glenn Goddard	CFO	Sell	5,365	$29.46	$158,052.90	40,585
1/3/2024	John M Leonard	CEO	Sell	19,223	$29.46	$566,309.58	846,486
10/31/2023	Muna Bhanji	Director	Sell	265	$23.90	$6,333.50	11,996
7/31/2023	Muna Bhanji	Director	Sell	265	$42.33	$11,217.45	12,261
7/6/2023	Muna Bhanji	Director	Sell	1,867	$39.30	$73,373.10	12,526
7/3/2023	Eliana Clark	EVP	Sell	360	$40.51	$14,583.60	45,146
6/20/2023	Eliana Clark	EVP	Sell	5,000	$45.00	$225,000.00	45,146
1/4/2023	Glenn Goddard	CFO	Sell	2,427	$37.21	$90,308.67	15,404
1/4/2023	John M Leonard	CEO	Sell	6,673	$37.21	$248,302.33	766,825
1/4/2023	Laura Sepp-Lorenzino	EVP	Sell	2,508	$37.21	$93,322.68	19,959

See Full Table

SEC Filings (Institutional Ownership Changes) for Intellia Therapeutics (NASDAQ:NTLA)

88.77% of Intellia Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intellia Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	699,814	$8.16M	0.0%	+8.5%	0.676%
3/18/2025	California State Teachers Retirement System	90,638	$1.06M	0.0%	+4.1%	0.088%
2/25/2025	Polar Asset Management Partners Inc.	282,400	$3.29M	0.0%	+1,144.1%	0.277%
2/19/2025	GF Fund Management CO. LTD.	2,139	$25K	0.0%	N/A	0.002%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	483,185	$5.63M	0.0%	+5.0%	0.474%
2/17/2025	Voloridge Investment Management LLC	1,526,994	$17.81M	0.1%	+226.8%	1.499%
2/17/2025	Vestal Point Capital LP	525,000	$6.12M	0.4%	N/A	0.515%
2/17/2025	Squarepoint Ops LLC	101,417	$1.18M	0.0%	+58.8%	0.100%
2/17/2025	Two Sigma Advisers LP	1,998,317	$23.30M	0.1%	+94.5%	1.962%
2/17/2025	Two Sigma Investments LP	1,843,743	$21.50M	0.0%	+88.1%	1.810%
2/17/2025	Teza Capital Management LLC	26,065	$0.30M	0.0%	+74.3%	0.026%
2/17/2025	Tema Etfs LLC	148,167	$1.73M	0.7%	N/A	0.145%
2/17/2025	Second Line Capital LLC	131,122	$1.53M	0.4%	N/A	0.129%
2/17/2025	Shell Asset Management Co.	29,975	$0.35M	0.0%	+45.7%	0.029%
2/17/2025	Sherbrooke Park Advisers LLC	22,515	$0.26M	0.1%	N/A	0.022%
2/17/2025	Sphera Funds Management LTD.	466,080	$5.43M	1.0%	+60.1%	0.458%
2/17/2025	Polar Asset Management Partners Inc.	282,400	$3.29M	0.0%	+1,144.1%	0.277%
2/17/2025	ProShare Advisors LLC	33,404	$0.39M	0.0%	+38.0%	0.033%
2/17/2025	Patient Square Capital LP	215,981	$2.52M	0.9%	+68.0%	0.212%
2/17/2025	Nuveen Asset Management LLC	260,697	$3.04M	0.0%	-28.7%	0.256%
2/17/2025	Millennium Management LLC	668,926	$7.80M	0.0%	+190.5%	0.657%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	227,255	$2.65M	0.0%	+7.5%	0.223%
2/17/2025	Lazard Asset Management LLC	109,500	$1.28M	0.0%	+7.3%	0.108%
2/17/2025	Hudson Bay Capital Management LP	512,300	$5.97M	0.0%	+52.9%	0.503%
2/17/2025	Granahan Investment Management LLC	306,510	$3.57M	0.1%	+8.1%	0.301%
2/17/2025	Ensign Peak Advisors Inc	39,169	$0.46M	0.0%	+2.9%	0.038%
2/17/2025	Deutsche Bank AG	252,501	$2.94M	0.0%	+12.1%	0.248%
2/17/2025	Cetera Investment Advisers	13,148	$0.15M	0.0%	-26.7%	0.013%
2/17/2025	Brevan Howard Capital Management LP	108,351	$1.26M	0.0%	+626.3%	0.106%
2/17/2025	Bridgefront Capital LLC	24,521	$0.29M	0.1%	+68.1%	0.024%
2/17/2025	Capstone Investment Advisors LLC	108,665	$1.27M	0.0%	+77.8%	0.107%
2/17/2025	Baker BROS. Advisors LP	644,116	$7.51M	0.1%	N/A	0.632%
2/17/2025	Bank of America Corp DE	639,696	$7.46M	0.0%	-10.7%	0.628%
2/17/2025	Benjamin Edwards Inc.	64,065	$0.75M	0.0%	+11.1%	0.063%
2/17/2025	BNP Paribas Financial Markets	438,458	$5.11M	0.0%	+78.0%	0.430%
2/17/2025	Algert Global LLC	69,354	$0.81M	0.0%	+13.6%	0.068%
2/17/2025	Aptus Capital Advisors LLC	139,278	$1.62M	0.0%	N/A	0.137%
2/14/2025	PDT Partners LLC	327,608	$3.82M	0.3%	+2,111.5%	0.322%
2/14/2025	Schonfeld Strategic Advisors LLC	145,502	$1.70M	0.0%	+7.6%	0.143%
2/14/2025	Northern Trust Corp	979,137	$11.42M	0.0%	+13.0%	0.961%
2/14/2025	The Manufacturers Life Insurance Company	47,915	$0.56M	0.0%	-10.5%	0.047%
2/14/2025	Aquatic Capital Management LLC	182,434	$2.13M	0.1%	+98.7%	0.179%
2/14/2025	Virtus ETF Advisers LLC	5,242	$61K	0.0%	+47.7%	0.005%
2/14/2025	Two Sigma Securities LLC	13,108	$0.15M	0.0%	N/A	0.013%
2/14/2025	Voya Investment Management LLC	28,829	$0.34M	0.0%	-7.1%	0.028%
2/14/2025	Syon Capital LLC	14,008	$0.16M	0.0%	N/A	0.014%
2/14/2025	Coppell Advisory Solutions LLC	11,591	$0.13M	0.0%	N/A	0.011%
2/14/2025	Price T Rowe Associates Inc. MD	39,295	$0.46M	0.0%	-93.3%	0.039%
2/14/2025	Hsbc Holdings PLC	51,536	$0.60M	0.0%	+47.4%	0.051%
2/14/2025	Stifel Financial Corp	397,761	$4.64M	0.0%	+320.4%	0.391%
2/14/2025	Tower Research Capital LLC TRC	8,148	$95K	0.0%	+28.5%	0.008%
2/14/2025	MetLife Investment Management LLC	59,187	$0.69M	0.0%	+6.3%	0.058%
2/14/2025	Curi RMB Capital LLC	29,881	$0.35M	0.0%	-23.7%	0.029%
2/14/2025	Dimensional Fund Advisors LP	1,976,212	$23.04M	0.0%	+36.5%	1.940%
2/13/2025	Marshall Wace LLP	95,339	$1.11M	0.0%	N/A	0.094%
2/13/2025	Jump Financial LLC	362,637	$4.23M	0.1%	+94.2%	0.356%
2/13/2025	Guggenheim Capital LLC	59,589	$0.70M	0.0%	-11.0%	0.059%
2/13/2025	XTX Topco Ltd	43,908	$0.51M	0.0%	+194.6%	0.043%
2/13/2025	Mariner LLC	14,820	$0.17M	0.0%	-14.4%	0.015%
2/13/2025	Barclays PLC	311,632	$3.63M	0.0%	+6.4%	0.306%
2/13/2025	Evolutionary Tree Capital Management LLC	47,406	$0.55M	0.6%	+34.0%	0.047%
2/13/2025	Rockefeller Capital Management L.P.	137,838	$1.61M	0.0%	+81.3%	0.135%
2/13/2025	Sterling Capital Management LLC	3,198	$37K	0.0%	+866.2%	0.003%
2/13/2025	Kennedy Capital Management LLC	12,847	$0.15M	0.0%	+22.7%	0.013%
2/13/2025	Raymond James Financial Inc.	411,077	$4.79M	0.0%	N/A	0.404%
2/13/2025	Martingale Asset Management L P	21,399	$0.25M	0.0%	N/A	0.021%
2/13/2025	Renaissance Technologies LLC	98,700	$1.15M	0.0%	N/A	0.097%
2/13/2025	FIL Ltd	159,671	$1.86M	0.0%	+737.6%	0.157%
2/13/2025	Legal & General Group Plc	106,767	$1.25M	0.0%	+10.6%	0.105%
2/13/2025	Invesco Ltd.	96,434	$1.12M	0.0%	+4.0%	0.095%
2/13/2025	Bank of Montreal Can	35,586	$0.42M	0.0%	N/A	0.035%
2/13/2025	Federated Hermes Inc.	3,845	$45K	0.0%	-99.9%	0.004%
2/13/2025	Aristides Capital LLC	15,600	$0.18M	0.0%	N/A	0.015%
2/13/2025	Himension Capital Singapore PTE. LTD.	985,715	$11.49M	0.8%	-8.4%	0.968%
2/13/2025	Russell Investments Group Ltd.	117,415	$1.37M	0.0%	-40.9%	0.115%
2/13/2025	Envestnet Asset Management Inc.	66,654	$0.78M	0.0%	-16.7%	0.065%
2/13/2025	Sit Investment Associates Inc.	85,500	$1M	0.0%	+42.7%	0.084%
2/13/2025	Wells Fargo & Company MN	277,692	$3.24M	0.0%	+38.3%	0.273%
2/13/2025	Resona Asset Management Co. Ltd.	3,668	$43K	0.0%	N/A	0.004%
2/12/2025	ExodusPoint Capital Management LP	105,827	$1.23M	0.0%	+98.4%	0.104%
2/12/2025	Arete Wealth Advisors LLC	10,272	$0.12M	0.0%	N/A	0.010%
2/12/2025	Bryce Point Capital LLC	26,083	$0.30M	0.1%	N/A	0.026%
2/12/2025	Trexquant Investment LP	667,632	$7.79M	0.1%	N/A	0.656%
2/12/2025	Geode Capital Management LLC	2,389,240	$27.87M	0.0%	+2.0%	2.346%
2/12/2025	Alliancebernstein L.P.	265,318	$3.09M	0.0%	-87.9%	0.260%
2/12/2025	Wellington Management Group LLP	699,814	$8.16M	0.0%	+8.5%	0.687%
2/12/2025	CIBC Private Wealth Group LLC	4,611	$55K	0.0%	-45.0%	0.005%
2/12/2025	Schroder Investment Management Group	24,000	$0.27M	0.0%	-72.1%	0.024%
2/12/2025	Norges Bank	30,010	$0.35M	0.0%	N/A	0.029%
2/12/2025	IQ EQ FUND MANAGEMENT IRELAND Ltd	54,657	$0.64M	0.1%	+137.3%	0.054%
2/12/2025	NEOS Investment Management LLC	127,826	$1.49M	0.0%	-18.2%	0.126%
2/12/2025	Mitsubishi UFJ Asset Management Co. Ltd.	17,293	$0.21M	0.0%	+67.6%	0.017%
2/11/2025	EntryPoint Capital LLC	32,425	$0.38M	0.2%	N/A	0.032%
2/11/2025	Interchange Capital Partners LLC	14,451	$0.16M	0.1%	-28.8%	0.014%
2/11/2025	Congress Wealth Management LLC DE	20,000	$0.23M	0.0%	N/A	0.020%
2/11/2025	Vanguard Group Inc.	10,190,053	$118.82M	0.0%	+5.8%	10.005%
2/11/2025	LPL Financial LLC	54,041	$0.63M	0.0%	-4.5%	0.053%
2/11/2025	KLP Kapitalforvaltning AS	21,600	$0.25M	0.0%	N/A	0.021%
2/11/2025	American Century Companies Inc.	453,821	$5.29M	0.0%	+3.5%	0.446%
2/11/2025	Contrarius Group Holdings Ltd	1,011,863	$11.80M	0.7%	N/A	0.993%

Data available starting January 2016

See Full Table

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $8.07

$8.03

$8.43

50 Day Range

MA: $9.98

$8.07

$12.28

52 Week Range

Now: $8.07

$8.03

$28.18

Volume

2,760,148 shs

Average Volume

2,189,823 shs

Market Capitalization

$835.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Who are the company insiders with the largest holdings of Intellia Therapeutics?: Intellia Therapeutics' top insider investors include:
John M Leonard (CEO)
James Basta (EVP)
Eliana Clark (EVP)
David Lebwohl (EVP)
Michael P Dube (CAO)
Laura Sepp-Lorenzino (EVP)
Glenn Goddard (CFO)
Muna Bhanji (Director)
Learn More about top insider investors at Intellia Therapeutics.
Who are the major institutional investors of Intellia Therapeutics?: Intellia Therapeutics' top institutional shareholders include:
ARK Investment Management LLC — 12.31%
Vanguard Group Inc. — 10.00%
Regeneron Pharmaceuticals Inc. — 3.64%
Sumitomo Mitsui Trust Group Inc. — 2.94%
Nikko Asset Management Americas Inc. — 2.94%
Geode Capital Management LLC — 2.35%
Learn More about top institutional investors of Intellia Therapeutics stock.
Which institutional investors are selling Intellia Therapeutics stock?: Within the previous quarter, NTLA stock was sold by these institutional investors:
Federated Hermes Inc.
Alliancebernstein L.P.
Price T Rowe Associates Inc. MD
Chevy Chase Trust Holdings LLC
Sumitomo Mitsui Trust Group Inc.
Nikko Asset Management Americas Inc.
Nuveen Asset Management LLC
Walleye Capital LLC
In the previous year, company insiders that have sold Intellia Therapeutics company stock include:
John M Leonard (CEO)
James Basta (EVP)
Eliana Clark (EVP)
David Lebwohl (EVP)
Learn More investors selling Intellia Therapeutics stock.
Which institutional investors are buying Intellia Therapeutics stock?: Within the last quarter, NTLA stock was purchased by institutional investors including:
Regeneron Pharmaceuticals Inc.
Voloridge Investment Management LLC
Contrarius Group Holdings Ltd
Two Sigma Advisers LP
Two Sigma Investments LP
Trexquant Investment LP
Baker BROS. Advisors LP
Vanguard Group Inc.